Oculocutaneous albinism type 1
Learn about Oculocutaneous albinism type 1, its reported features, relevant specialists, and questions to discuss at a medical consultation.
Also known as: OCA1
The sources compiled here do not cover: diagnosis, treatment, prevention, prognosis, prevalence. Ask the treating doctor about these.
What it is
From: Orphanet
A form of oculocutaneous albinism (OCA) characterized by a spectrum of hypopigmentation of skin hair and eyes, ranging from little or no pigmentation to localized pigementation. Nystagmus, photophobia and reduced visual acuity are frequently present. The subtypes include OCA1A, OCA1B, type 1 minimal pigment oculocutaneous albinism (OCA1-MP) and type 1 temperature sensitive oculocutaneous albinism (OCA1-TS).
Reported clinical features and what the terms mean
The following findings are associated with this condition in Orphanet. They are not a checklist for diagnosing yourself, and they do not all occur in every affected person. Some are examination, imaging or laboratory findings that cannot be recognised at home.
The frequency labels describe how often a finding was reported among people with the condition in the source. They do not give the chance that a person with that symptom has the condition. Definitions below reproduce HPO terminology; they explain the term, not the likely severity in an individual.
- Abnormality of visual evoked potentials · Very frequent (99-80%)
- An anomaly of visually evoked potentials (VEP), which are electrical potentials, initiated by brief visual stimuli, which are recorded from the scalp overlying the visual cortex.
- Blue irides · Very frequent (99-80%)
- A markedly blue coloration of the iris.
- Cutaneous photosensitivity · Very frequent (99-80%)
- An increased sensitivity of the skin to light. Photosensitivity may result in a rash upon exposure to the sun (which is known as photodermatosis). Photosensitivity can be diagnosed by phototests in which light is shone on small areas of skin.
- Generalized hypopigmentation of hair · Very frequent (99-80%)
- Reduced pigmentation of hair diffusely.
- Hypoplasia of the fovea · Very frequent (99-80%)
- Underdevelopment of the fovea centralis.
- Iris hypopigmentation · Very frequent (99-80%)
- An abnormal reduction in the amount of pigmentation of the iris.
- Iris transillumination defect · Very frequent (99-80%)
- Transmission of light through the iris as visualized upon slit lamp examination or infrared iris transillumination videography. The light passes through defects in the pigmentation of the iris.
- Nystagmus · Very frequent (99-80%)
- Rhythmic, involuntary oscillations of one or both eyes related to abnormality in fixation, conjugate gaze, or vestibular mechanisms.
- Optic nerve misrouting · Very frequent (99-80%)
- Abnormal decussation of the visual pathways, typically identified using visual evoked potentials (VEP) (asymmetrical distribution of the VEP over the posterior scalp).
- Photophobia · Very frequent (99-80%)
- Excessive sensitivity to light with the sensation of discomfort or pain in the eyes due to exposure to bright light.
- Abnormal morphology of the choroidal vasculature · Very frequent (99-80%)
- Depigmented fundus · Very frequent (99-80%)
- Generalized hypopigmentation · Very frequent (99-80%)
- Reduced visual acuity · Very frequent (99-80%)
Other findings in the same source
From: Orphanet
Additional reported features include Amblyopia (Frequent (79-30%)); Strabismus (Frequent (79-30%)); White eyebrow (Frequent (79-30%)); White eyelashes (Frequent (79-30%)); Thickened skin (Occasional (29-5%)); Actinic keratosis (Very rare (<4-1%)); Neoplasm of the skin (Very rare (<4-1%)). This is a selected summary, not a complete description of the condition.
When it may begin
From: Orphanet
Infancy; Neonatal
Inheritance in the source
From: Orphanet
Autosomal recessive
Understanding the inheritance label
From: MedlinePlus Genetics
An autosomal recessive pattern usually involves disease-causing changes in both copies of a gene. Parents may each carry one altered copy without having the condition themselves. A genetic counsellor can explain carrier testing and reproductive implications using the actual laboratory findings, rather than the condition name alone.
Which doctor should you see?
The suggested department for discussing Oculocutaneous albinism type 1 is Dermatology, with a dermatologist as the relevant type of clinician. Dermatologist; paediatric services for children as appropriate.
This is an editorial referral starting point. The appropriate clinic depends on the person’s age, symptoms, previous diagnosis and local services. The first clinician can decide whether another specialty or a team is needed; a department label does not confirm the diagnosis.
How to prepare for an assessment
Bring a short timeline of the main symptoms: when they first appeared, whether they are constant or episodic, what seems to change them, and how they affect daily activities. Include previous reports, discharge summaries, current medicines and supplements, allergies, and any relevant family history. A dated record is more useful than trying to match every feature in an online article.
Ask the clinician what is already established and what remains uncertain. If a test is suggested, ask what question it answers, what its limitations are and how the result would change the next step. The information here is not an instruction to arrange every possible test. In children, bring growth, developmental and school information if it is relevant to the concern.
- Which features of the skin, hair or nails distinguish the possibilities?
- Would photographs over time help document the changes?
- What should be expected from treatment, and how will irritation or other adverse effects be managed?
Treatment discussions and follow-up
The material gathered for this draft does not provide a complete condition-specific treatment pathway for Oculocutaneous albinism type 1. That gap does not mean that treatment is unavailable. A clinician needs to establish the diagnosis and review current guidance before recommending medicines, procedures, rehabilitation or other support.
Before leaving the appointment, clarify the next review date, who will communicate results, and whom to contact if the situation changes. Discuss difficulties with sleep, work, school, mobility, eating or emotional wellbeing when these are relevant. Practical support may require coordination between the treating clinician and other services.
The collected references do not establish a complete prevention or long-term outlook section for this entry. Missing information should not be interpreted as proof that prevention is impossible or that a particular outcome is inevitable. Ask what is known for the exact subtype, stage and personal circumstances, and which uncertainties remain.
When to seek emergency help
Severe breathing difficulty, collapse, new stroke-like symptoms, a seizure that is prolonged or repeated without recovery, uncontrolled major bleeding, or an immediate risk of self-harm require emergency help. In India, call 112 or reach the nearest emergency department. This is a general, non-exhaustive warning list; it is not a condition-specific triage tool.
This condition is usually assessed by a dermatologist. Every profile shows the doctor’s registration and what has been checked.
Sources
- Orphanet — Oculocutaneous albinism type 1 — Orphadata Science, CC BY 4.0
- Human Phenotype Ontology Consortium — terminology definitions — HPO licence; definitions reproduced without alteration
- MedlinePlus Genetics — inheritance patterns — Public-domain Genetics education
- Government of India — Emergency Response Support System — Official reference for India emergency number
Source: MedlinePlus, National Library of Medicine. Orphadata Science: Free access data from Orphanet. © INSERM 1999; July 2026 data, CC BY 4.0. This product uses the Human Phenotype Ontology (hp/releases/2026-09-01). Only sources listed for this article apply. Source material has been selected and arranged; HPO definitions are reproduced without alteration. No source organisation endorses this compilation. Köhler S et al. The Human Phenotype Ontology project: linking molecular biology and disease through phenotype data. Nucleic Acids Research 2014;42(D1):D966–D974. doi:10.1093/nar/gkt1026.
General information, not advice about your situation. Errors can be reported through the corrections process. Reference TDI-C-1742.